Farrugia D C, Norman A R, Nicolson M C, Gore M, Bolodeoku E O, Webb A, Cunningham D
Section of Medicine, Royal Marsden Hospital, Sutton, Surrey, U.K.
Eur J Cancer. 1996 Dec;32A(13):2256-61. doi: 10.1016/s0959-8049(96)00264-x.
This is a retrospective review of 101 patients with unknown primary carcinoma (UPC) treated between 1989 and 1994, on whom data were collected prospectively. 92 patients received platinum-based chemotherapy and 9 had single agent 5-fluorouracil (5-FU). In the platinum group, an objective response rate of 37.2% was seen, with a median duration of 4.5 months (range 1.9-17.5). There were no responses with 5-FU alone, while median survival was 6.4 months and was not different from the platinum group (P = 0.09). Considerable symptomatic resolution was noted, although the contribution of chemotherapy alone to this is difficult to define. The impact of tumour response on quality of life and survival in UPC requires further elucidation in prospective studies with a "best supportive care' arm. The superiority of platinum-based treatments reported in selected subgroups cannot be applied to the whole spectrum of UPC.
这是一项对1989年至1994年间接受治疗的101例原发性不明癌（UPC）患者的回顾性研究，前瞻性收集了这些患者的数据。92例患者接受了铂类化疗，9例接受单药5-氟尿嘧啶（5-FU）治疗。在铂类治疗组中，客观缓解率为37.2%，中位缓解持续时间为4.5个月（范围1.9 - 17.5个月）。单独使用5-FU未出现缓解，中位生存期为6.4个月，与铂类治疗组无差异（P = 0.09）。观察到有相当程度的症状缓解，尽管单独化疗对此的贡献难以界定。在有“最佳支持治疗”组的前瞻性研究中，肿瘤反应对UPC患者生活质量和生存的影响需要进一步阐明。在特定亚组中报道的铂类治疗的优越性不能应用于整个UPC患者群体。
